Trial · NCT01129674
A Long-Term, Open-Label, Study on Schizophrenia
NCT01129674, Phase 2, Phase 3, Terminated, Denovo Biopharma LLC
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Long-Term, Open-Label, Study on Schizophrenia. Trials, record NCT01129674. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01129674
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Long-Term, Open-Label, Study on Schizophrenia
- NCT number
- NCT01129674
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 560 participants, actual
- Lead sponsor
- Denovo Biopharma LLC
- Conditions
- Schizophrenia
- Interventions
- LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine
- First posted
- 2010-05-25
- Last updated
- 2026-09-14
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to discontinuation due to adverse events | Baseline through 52 weeks | |
| Secondary | Change from baseline to 52 weeks endpoint in PANSS (Positive and Negative Syndrome Scale) | Baseline, 52 weeks | |
| Secondary | Change from baseline to 52 week endpoint in Clinical Global Impression-Severity (CGI-S) | Baseline, 52 weeks | |
| Secondary | Change from baseline to 52 week endpoint in NSA-16 (16-item Negative Symptoms Assessment) | Baseline, 52 weeks | |
| Secondary | The number of patients with statistically significant changes (treatment emergent ideation and behavior; improvement) based on the Columbia Suicide Severity Rating Scale (C-SSRS) | 52 weeks, 104 weeks, end of study | |
| Secondary | Change from baseline to 52 week endpoint in PSP scale (Personal and Social Performance) | Baseline, 52 weeks | |
| Secondary | Change from baseline to 52 week endpoint in the SWN Scale (Subjective Well-Being Under Neuroleptic Treatment) | Baseline, 52 weeks | |
| Secondary | Change from baseline to 104 week endpoint in the Schizophrenia Resource Use Model (S-RUM) | Baseline, 104 weeks | |
| Secondary | Change from baseline to 104 week endpoint in the EuroQoL Questionnaire-5 Dimension (EQ-5D) | Baseline, 104 weeks | |
| Secondary | Change from 52 week to 104 week endpoint in PANSS (Positive and Negative Syndrome Scale) | 52 weeks, 104 weeks |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01129674
GET https://conductscience.org/api/trials/v1/NCT01129674/registered